Greven

This research aims to compare the outcomes and patient satisfaction of two commercially available trifocal toric intraocular lenses used in cataract surgery. The study focuses on measuring the distance-corrected intermediate visual acuity and assessing the safety of these lenses, which are designed to improve vision at near, distance, and intermediate ranges while reducing the need for glasses. These lenses also correct astigmatism and are part of an advanced premium range with specialized optical features. Participants will receive one of two types of trifocal toric intraocular lenses: the Optiflex TRIO or the AcrySof IQ PanOptix. Both are single-piece, foldable lenses implanted in the posterior chamber of the eye. Each lens has advanced aspheric optics and is designed to provide clear vision across all distances while correcting astigmatism. Patients are randomly assigned to receive one of these lenses during their cataract surgery. During the study, participants will be monitored to evaluate their visual acuity at intermediate distances six months after implantation. Researchers will also assess patient satisfaction and lens safety throughout the study. Various clinical evaluations and follow-ups will be conducted to gather data on the lenses' performance, with the goal of comparing the benefits and potential risks of each lens type.

Researchers are studying a new biological implant called Spongioflexae for partial meniscal replacement in patients with partial meniscal loss and related knee pain. The study aims to see if this novel graft can avoid or reduce problems seen with previous materials and improve patient outcomes compared to those who do not have surgery. Since there is currently no biological alternative available, this study is medically and economically important. The meniscus plays a key role in knee stability and pressure distribution, and partial meniscus loss can lead to arthritis and the need for knee replacement surgery over time. During the study, patients undergoing surgery will receive an antibiotic shot before the procedure. The Spongioflexae implant, made from demineralized human bone, will be arthroscopically placed into the meniscus defect and secured with sutures. The implant is flexible, porous, and designed to support cell ingrowth and tissue regeneration. Surgery lasts about 60-90 minutes, with a hospital stay of 2-3 days. Follow-up visits are scheduled at hospital discharge, 6 weeks, 6 months, 12 months, 24 months, and 5 years after surgery. Participants will be evaluated using several knee function and pain scores at these time points to assess the implant's effectiveness. The study also includes MRI imaging to monitor meniscus incorporation and joint health. Researchers will track safety, function, and long-term outcomes related to pain, knee function, and arthritis progression. The total follow-up period extends to 5 years, providing data on both short- and long-term effects of the implant.

Researchers are evaluating the safety and effectiveness of mesenchymal stem cells (MSC) derived from umbilical cord tissue (UC-MSC) for treating cartilage damage in the knee joint. This Phase I/IIa clinical trial is a multicenter, single-arm, open-label study involving patients aged 18 to 60 years with symptomatic cartilage defects. The study aims to monitor safety and collect initial data on the treatment's effects over a two-year period after surgery. Eligible patients will receive knee surgery on Day 0, during which the investigational product—10 to 20 million UC-MSC suspended in 1 ml and applied to a collagen carrier (Chondro-Gide®)—will be applied once directly to the cartilage defect. Follow-up visits are scheduled at regular intervals throughout the following 24 months to observe safety and gather efficacy data. Participants will undergo screening to confirm eligibility before treatment. During the study, they will be monitored through clinical assessments and data collection related to any serious adverse events within 24 months after surgery. The study focuses on safety outcomes primarily but also gathers information on treatment effects on the cartilage damage. The total participation duration for each patient is approximately two years post-surgery.